Company Overview
Company Type: Public Company
Website: kanebiotech.com
Number of Employees: -
Ticker: KNE (TSXV)
Year Founded: 2001


Business Description
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; and animal and human wound care solutions under the DispersinB name. It also offers scalp care products under the DermaKB brand name; and wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, Aledex, and DermaKB Biofilm brand names. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
2.6
Market Capitalization
8.6
TEV/Total Revenue
6.8x
EBITDA
(2.9)
Total Enterprise Value
17.8
TEV/EBITDA
NM
EBIT
(3.0)
Cash & ST Invst.
1.1
P/Diluted EPS Before Extra
NM
Net Income
(4.0)
Total Debt
8.1
Price/Tang BV
NM
Capital Expenditure
(0.1)
Total Assets
5.6
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-05-2023

Key Professionals
Name
Title
Edwards, Marc 
President, CEO & Director
Dupuis, Ray 
Chief Financial Officer
Schultz, Gregory S.
Chief Scientific Officer & Member of Scientific Advisory Board
Gorber, Lorne 
Investor Relations
Christofalos, Lori 
Vice President of Quality & Compliance
Nachtigall, Wendy 
Director of Marketing
Cole, Kevin 
President & CEO of STEM Animal Health Inc
Sendey, Nicole 
Investor Relations Adviser
Ahrens-Townsend, Mark 
Advisor

Key Board Members
Name
Title
Renaud, Richard J.
Chairman
Edwards, Marc 
President, CEO & Director
Renaud, Philip R.
Vice Chairman
Schultz, Gregory S.
Chief Scientific Officer & Member of Scientific Advisory Board
Guay, Gordon 
Chairman of Scientific Advisory Board
Morin, Georges E.
Independent Director
Gluck, Rashieda 
Member of Scientific Advisory Board
Huizinga, Robert B.
Member of Scientific Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
290-100 Innovation Drive | Winnipeg, MB | R3T 6G2 | Canada
Phone: 204 453 1301   

Prior Investors
Genesys Venture Inc. (Albert Friesen, P. Enns), Manitoba Science and Technology Fund, L.P., SciTech Management Inc.

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.07
Market Cap (mm)
8.6
Open
 0.07
Shares Out. (mm)
131.8
Previous Close
 0.07
Float %
62.7%
Change on Day
0.00
Shares Sold Short (mm)
-
Change % on Day
0.0%
Dividend Yield %
-
Day High/Low
 0.07/ 0.07
Diluted EPS Excl. Extra Items
(0.03)
52 wk High/Low
 0.15/ 0.06
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0010
Avg 3M Dly Vlm (mm)
0.03
Beta 5Y
0.43


 
Delayed Quote** | Last Updated on Oct-06-2023 09:46 AM (GMT-5)
TSXV:KNE - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Vinson Biotech Inc
Vinson Biotech Inc. was acquired by Kane Biotech Inc. on 10/1/2004 in a reverse merger transation.

United States and Canada
Biotechnology
-
-
-
STEM Animal Health Inc.
STEM Animal Health Inc. develops oral care products for pets to treat biofilm-related ailments. It offers water additives, oral spray, toothpaste and toothbrush, dental chews, and dental wipes. The company was incorporated in 2020 and is based in Winnipeg, Canada. STEM Animal Health Inc. operates as a subsidiary of Kane Biotech Inc.

United States and Canada
Pharmaceuticals
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Aug-03-2023
Sep-12-2023
Private Placement
Target
Kane Biotech Inc. (TSXV:KNE)


0.37
Mar-15-2022
May-17-2022
Private Placement
Target
Kane Biotech Inc. (TSXV:KNE)


0.78
Dec-04-2019
Feb-24-2020
Private Placement
Target
Kane Biotech Inc. (TSXV:KNE)


2.64
Jul-17-2018
Jul-17-2018
Private Placement
Target
Kane Biotech Inc. (TSXV:KNE)


0.38
Jun-01-2017
Aug-17-2017
Private Placement
Target
Kane Biotech Inc. (TSXV:KNE)


3.27
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-12-2023
Debt Financing Related
Kane Biotech Inc. Announces Amendments to Its Credit Facility
Sep-12-2023
Private Placements
Kane Biotech Inc. announced that it has received CAD 0.5 million in funding
Aug-29-2023
Earnings Calls
Kane Biotech Inc., Q2 2023 Earnings Call, Aug 29, 2023
Aug-03-2023
Debt Financing Related
Kane Biotech Announces Proposed Amendments to Its Credit Facility
Aug-03-2023
Private Placements
Kane Biotech Inc. announced that it expects to receive CAD 0.5 million in funding


Advisors
Most Recent Auditor
MNP LLP
Key development Advisor
Research Capital Corporation


Most Recent Auditor
Meyers Norris Penny LLP - MNP LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
ValuEngine, Inc.

Oct 02, 2023 06:21 AM
KNE
ValuEngine - Toronto Quantitative Stock Report for KNE
Reports
5
GlobalData

Sep 28, 2023 06:18 AM
KNE
Kane Biotech Inc (KNE.CVE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
42
GlobalData

Sep 21, 2023 05:43 AM
KNE
Kane Biotech Inc (KNE.CVE) - Medical Equipment - Deals and Alliances Profile
Reports
36
GlobalData

Sep 14, 2023 11:21 PM
KNE
Kane Biotech Inc (KNE.CVE) - Medical Devices Product Pipeline Summary
Reports
58
MarketLine

Sep 14, 2023 06:01 AM
KNE
Kane Biotech Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
274
GlobalData

Sep 12, 2023 03:52 AM
KNE
Kane Biotech Inc (KNE.CVE) - Financial Analysis Review
Reports
187
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Jun 18, 2023 06:00 PM
KNE
Rating Update for Kane Biotech Inc
EPS Estimates*
3
GlobalData

Jun 14, 2023 02:57 AM
KNE
Kane Biotech Inc (KNE.CVE) - Financial Analysis Review
Reports
186
GlobalData

May 23, 2023 04:25 AM
KNE
Kane Biotech Inc (KNE.CVE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
42
GlobalData

May 23, 2023 04:24 AM
KNE
Kane Biotech Inc (KNE.CVE) - Medical Equipment - Deals and Alliances Profile
Reports
38


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Renaud, Philip R.

27,389,711

20.77

1.6

Jun-23-2023


Renaud FCA, Richard J.

14,630,333

11.10

0.9

Sep-11-2023


Edwards, Marc 

5,888,142

4.47

0.4

Sep-11-2023


Dupuis, Ray 

985,404

0.75

0.1

Sep-11-2023


Morin B.ADM, BA, ICD.D, Georges E.

150,000

0.11

0.0

Jun-23-2023


Nawacki CA, CPA, MBA, Mark H.

133,000

0.10

0.0

Apr-19-2022


Prichard FRCP(C), M.D., Sarah S.

50,000

0.04

0.0

Apr-19-2022



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Renaud FCA, Richard J.
14,630,333
14,630,333
Dupuis, Ray 
985,404
125,000
Edwards, Marc 
5,888,142
125,000

Top Sellers
No Top Sellers data available.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Aledex, AloSera, Apoquel, Biofilm, Bluestem, Bluestem Dental Chews, Bluestem Dental Wipes, Bluestem Powder Water Additive, Bluestem Rawhide Chews, Coactiv+ (Future), DermaKB, DispersinB (Future), Goldstem, KBI Antibacterial Disinfectant, KBI-4258, KBI-5898 (Future), Licensing of DispersinB, Licensing of StrixNB, PS/CHX (Future), Silkstem, StrixNB


Upcoming Events
Date/Time
Type
Nov-24-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-12-2023
-
Kane Biotech Inc. (TSXV:KNE)
SEDAR
Material Change Report
197 KB
Sep-12-2023
-
Kane Biotech Inc. (TSXV:KNE)
SEDAR
News Releases
32 KB
Aug-29-2023
Jun-30-2023
Kane Biotech Inc. (TSXV:KNE)
SEDAR
Interim Financial Statements
361 KB
Aug-29-2023
-
Kane Biotech Inc. (TSXV:KNE)
SEDAR
News Releases
156 KB
Aug-22-2023
-
Kane Biotech Inc. (TSXV:KNE)
SEDAR
News Releases
22 KB
Aug-03-2023
-
Kane Biotech Inc. (TSXV:KNE)
SEDAR
News Releases
31 KB
Aug-02-2023
-
Kane Biotech Inc. (TSXV:KNE)
SEDAR
News Releases
26 KB
Jun-23-2023
-
Kane Biotech Inc. (TSXV:KNE)
SEDAR
News Releases
19 KB
May-30-2023
-
Kane Biotech Inc. (TSXV:KNE)
SEDAR
Documents Affecting the Rights of Security Holders
317 KB
May-29-2023
Mar-31-2023
Kane Biotech Inc. (TSXV:KNE)
SEDAR
Interim Financial Statements
299 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Renaud FCA, Richard J. (Chairman)
Sep-11-2023
Common Voting Shares
3,125,000
251,518
Open Market Acquisition
27.16
Multiple
Dupuis, Ray  (Chief Financial Officer)
Sep-11-2023
Common Voting Shares
125,000
10,061
Open Market Acquisition
14.53
Multiple
Edwards, Marc  (President, CEO & Director)
Sep-11-2023
Common Voting Shares
125,000
10,061
Open Market Acquisition
2.17
Multiple
Edwards, Marc  (President, CEO & Director)
May-16-2022
Common Voting Shares
3,100,000
328,469
Private Acquisition
116.40
Multiple
Dupuis, Ray  (Chief Financial Officer)
Feb-04-2022
Common Voting Shares
100,000
13,125
Open Market Acquisition
13.15
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Renaud, Richard J.
Chairman
514.878.1800
-
rjr@tngcorporation.com
Edwards, Marc 
President, CEO & Director
(514) 910-6991
-
medwards@kanebiotech.com
Renaud, Philip R.
Vice Chairman
204 453 1301
-

Schultz, Gregory S.
Chief Scientific Officer & Member of Scientific Advisory Board
204 453 1301
-

Guay, Gordon 
Chairman of Scientific Advisory Board
204 453 1301
-

Morin, Georges E.
Independent Director
204 453 1301
-

Gluck, Rashieda 
Member of Scientific Advisory Board
204 453 1301
-

Huizinga, Robert B.
Member of Scientific Advisory Board
204 453 1301
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Edwards, Marc 
President, CEO & Director
(514) 910-6991
-
medwards@kanebiotech.com
Dupuis, Ray 
Chief Financial Officer
+1 (204) 298-2200
-
rdupuis@kanebiotech.com
Schultz, Gregory S.
Chief Scientific Officer & Member of Scientific Advisory Board
204 453 1301
-

Gorber, Lorne 
Investor Relations
204 453 1301
-
lgorber@kanebiotech.com
Christofalos, Lori 
Vice President of Quality & Compliance
204 453 1301
-

Nachtigall, Wendy 
Director of Marketing
204 453 1301
-

Cole, Kevin 
President & CEO of STEM Animal Health Inc
204 453 1301
-

Sendey, Nicole 
Investor Relations Adviser
250-327-8675
-
nsendey@kanebiotech.com
Ahrens-Townsend, Mark 
Advisor
(204) 477-7592
-
-
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
